Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
Jefferies Remains a Buy on InMode (INMD)
InMode Analyst Ratings
UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating
Needham: Reiterates that InMode (INMD.US) holds the rating.
InMode Analyst Ratings
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
Barclays: Maintaining the InMode (INMD.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $34.00 to $33.00.
InMode Analyst Ratings
Barclays Maintains Overweight on InMode, Lowers Price Target to $33
Barclays Keeps Their Buy Rating on InMode (INMD)
Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)
Needham Sticks to Their Hold Rating for InMode (INMD)
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), InMode (INMD) and Teladoc (TDOC)
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Evolent Health (EVH) and InMode (INMD)
InMode Receives Buy Rating From Baird Analyst Amidst Promising Outlook and Undervalued Stock
InMode Analyst Ratings
UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating
Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)